GlassScriptPhysician profile
Anthony C Wiseman
NPI 1528487907
$1,293.05
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $193.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $129.60 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $116.84 | 2019 | |
| Adaptive Biotechnologies Corporation | $104.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.80 | 2019-2020 | |
| Pfizer INC. | $82.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $77.00 | 2019 | |
| Lilly USA, LLC | $73.34 | 2019-2020 | |
| Amgen INC. | $49.98 | 2019-2020 | |
| Incyte Corporation | $49.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $49.47 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.22 | 2020 | |
| Astellas Pharma US INC | $21.69 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17.72 | 2019 | |
| Genzyme Corporation | $16.72 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Wiseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.